Study on epigenetic regulatory mechanism of MBD4 with a germline loss-of-function mutation (rs140693) responsible for retinoblastoma chemoresistance via the cell cycle and apoptotic pathways

Li Zhang; Wenping Song; Junting Wang; Yeling Zhao; Chenyu Yuan; Zhilong Ruan; Jiaqi Chen; Junyang Zhao; Hongjuan Yao; Hebing Chen; Chengyue Zhang; Liang LI

doi:10.1016/j.phrs.2026.108098

Study on epigenetic regulatory mechanism of MBD4 with a germline loss-of-function mutation (rs140693) responsible for retinoblastoma chemoresistance via the cell cycle and apoptotic pathways

Pharmacological Research 2026 Open access

Read full text

Authors: Li Zhang, Wenping Song, Junting Wang, Yeling Zhao, Chenyu Yuan, Zhilong Ruan, Jiaqi Chen, Junyang Zhao, Hongjuan Yao, Hebing Chen, Chengyue Zhang, Liang LI

DOI: 10.1016/j.phrs.2026.108098

Cited by: 1

References: 72

Abstract

) cells after MBD4-WT was restored. In the present study, our findings indicate that depletion or mutation of MBD4 interferes with the activation of the cell cycle and apoptosis via epigenetic regulation, thereby reducing drug susceptibility. It provides new insights into the role in RB chemoresistance of MBD4 as an epigenetic regulator, which might fuel the development of new RB-targeted strategies.

Fields of Study & Subjects

Ocular Oncology and Treatments Cancer Hypoxia and Metabolism Cancer-related Molecular Pathways

Publication details

Journal / source: Pharmacological Research
Publisher: Elsevier BV
Volume: 224
Pages: 108098–108098
Publication date: 12 January 2026
Language: EN

References 72